EU Health Regulator Approves GSK's RSV Shot for More Adults

The European Union health regulator recommended the expanded use of GSK's RSV vaccine in adults aged 50 to 59. The decision awaits formal approval from the European Commission. In other health news, Alzheimer's drug Leqembi was rejected, WHO sent polio vaccines to Gaza, and Indivior settled an opioid lawsuit.

The European Union health regulator has recommended extending the use of GSK's respiratory syncytial virus (RSV) vaccine to adults aged between 50 and 59. As is customary, this recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use now awaits formal approval by the European Commission.

In related developments, the European Union's drugs regulator has rejected Eisai and Biogen's Alzheimer's treatment, Leqembi. The decision was based on concerns that the risk of serious brain swelling outweighed its modest impact on slowing cognitive decline. This poses a significant challenge for the companies, as the drug has already seen slow adoption in the United States.

Meanwhile, the World Health Organization announced plans to send over one million polio vaccines to Gaza. This measure aims to protect children from the virus after it was detected in sewage samples. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the urgency, warning it's just a matter of time before the virus infects unprotected children.

(With inputs from agencies.)